# PRESTO (NCT03009981)

> A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: apalutamide; apalutamide plus abiraterone
- Indication: high-risk biochemically relapsed castration-sensitive prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03009981
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Alliance Foundation Trials, LLC.
- Conditions: Prostate Cancer
- Interventions: Apalutamide; LHRH Analogue; Abiraterone Acetate; Prednisone
- Enrollment: 503
- Primary outcome: PSA Progression-free Survival in the Intent-to-treat Population

## Indexed commentary on PRESTO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 2 podcast episodes
- 1 YouTube video

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=presto-nct03009981

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03009981", "email": "<work email>"}; the inbox owner confirms by the emailed link.